Promotions & Moves

Jubilant Therapeutics Appoints Chief Scientific Officer

Luca Rastelli brings more than 20 years of oncology drug discovery and development experience.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Jubilant Therapeutics Inc. has appointed Luca Rastelli, Ph.D. as Chief Scientific Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community. He reports directly to Syed Kazmi, Ph.D., Chief Executive Officer.   “Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team,” said Syed Kazmi, Ph.D., President a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters